

ASX ANNOUNCEMENT

26 June 2023

Shareholder update webinar

26 June 2023 – As previously announced, Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) is pleased to invite shareholders, investors and interested parties to an investor update webinar and Q&A with CEO, Peter Koetsier on Wednesday, 5 July 2023 at 11:00 am (AEST).

To attend the webinar, please pre-register via the following link:

https://us02web.zoom.us/webinar/register/WN_SXWVFXFhTnqaT0LE2eCF0w

After registering, you will receive a confirmation email containing information about joining the webinar.

Shareholders are encouraged to participate in this webinar by submitting questions in advance to:

contact@canngrouponlimited.com

A recording of the webinar will be available on the Company's website shortly after the live session.

Authorised for release by Deborah Ambrosini, Company Secretary, Cann Group Limited.

For all information please contact:

Peter Koetsier
CEO
Cann Group Limited
+61 3 9095 7088

contact@canngrouponlimited.com

Deborah Ambrosini
CFO & Company Secretary
Cann Group Limited
+61 3 9095 7088

deborah.ambrosini@canngrouponlimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is enhancing patients' lives by developing, producing, and supplying innovative cannabis medicines. The Company has research facilities and corporate headquarters in Melbourne and operates a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

Learn more at: www.canngrouponlimited.com | www.satipharm.com